Pharvaris, a Zug, Switzerland-based clinical-stage company, closed an $80m Series C financing bringing its total venture funding to over $160m to date.
The round was co-led by Viking Global Investors and General Atlantic, with participation from Cormorant Asset Management and current investors Foresite Capital, Bain Capital Life Sciences, venBio Partners, and Venrock Healthcare Capital Partners.
The proceeds from the Series C financing will fund the clinical advancement of the company’s pipeline of novel oral bradykinin-B2-receptor antagonists for the treatment of HAE, including both on-demand treatment and prophylactic prevention.
Led by Berndt Modig, Chief Executive Officer, Pharvaris is focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications. The company’s first product candidate, PHVS416 (PHA121 in soft capsules), is a potent, orally available bradykinin B2-receptor antagonist designed to block the effects of bradykinin during HAE attacks. Initiation of RAPIDe-1, a multi-center Phase 2 placebo-controlled on-demand study of PHVS416 in HAE patients, is expected in 2021. Pharvaris is also developing an orally available extended-release product containing PHA121 specifically for prophylaxis in HAE patients.